1.Efficacy of the transcatheter tricuspid valve replacement for patients with severe tricuspid regurgitation: Lux-Valve versus Lux-Valve Plus.
Yandan SUN ; Liang CAO ; Wei BAI ; Yuxi LI ; Jian YANG ; Guomeng JIANG ; Yang LIU ; Ping JIN ; Liwen LIU ; Xin MENG
Journal of Zhejiang University. Medical sciences 2025;54(2):213-218
OBJECTIVES:
To compare the efficacy of transcatheter tricuspid valve replacement (TTVR) using Lux-Valve and Lux-Valve Plus in patients with severe tricuspid regurgitation.
METHODS:
A total of 28 consecutive patients with severe tricuspid regurgitation who underwent TTVR with Lux-Valve (n=14) or Lux-Valve Plus (n=14) in the First Affiliated Hospital of the Air Force Medical University from August 2019 to November 2023 were enrolled. Transthoracic echocardiography was performed in all patients before and 6 months after the TTVR. The ultrasound indexes were compared before and 6 months after the TTVR in all patients and between Lux-Valve and Lux-Valve Plus groups.
RESULTS:
Compared with the Lux-Valve group, the Lux-Valve Plus group showed significantly reduced intraoperative bleeding and shorter postoperative hospital stays (both P<0.05). Six months after the TTVR, none of the patients exhibited more than a mild tricuspid valve regurgitation, and none of the patients had moderate or above perivalvular leakage except for one patient in the Lux-Valve Plus group who had a separation of the clamping member from the anterior tricuspid leaflet. The incidence of perivalvular leakage was significantly lower in the Lux-Valve Plus group (14.29%, 2/14) than in the Lux-Valve group (64.29%, 9/14, P<0.05). At 6 months after operation, the right chamber volume and right ventricle middle transverse diameter were reduced (both P<0.05); the peak blood flow velocity across the tricuspid valve, peak pressure gradient across the tricuspid valve, mean blood flow velocity of tricuspid valve, mean pressure gradient across the tricuspid valve and velocity time integral were increased in both groups (all P<0.05).Compared with the Lux-Valve group, the Lux-Valve Plus group showed higher left ventricular ejection fraction at 6 months postoperatively (P<0.05), while the rest of the indicators were not statistically different (all P>0.05).
CONCLUSIONS
The efficacy of using Lux-Valve and Lux-Valve Plus for TTVR in patients with severe tricuspid regurgitation is comparable. Six months after the TTVR, the right side of the heart has undergone reverse remodeling.While Lux-Valve Plus offers greater minimally invasive benefits, valve selection should consider device-specific characteristics and differences in individual patients.
Humans
;
Tricuspid Valve Insufficiency/surgery*
;
Male
;
Female
;
Heart Valve Prosthesis Implantation/methods*
;
Middle Aged
;
Aged
;
Tricuspid Valve/surgery*
;
Heart Valve Prosthesis
;
Treatment Outcome
;
Echocardiography
;
Adult
;
Cardiac Catheterization/methods*
2.Experimental study and clinical application of umbilical cord blood stem cells
Yandan LIANG ; Peifu WANG ; Jichen DU
Chinese Journal of Tissue Engineering Research 2009;13(27):5349-5352
Many studies have shown that experimental umbilical cord blood stem calls are even more primitive, more self-renewal, differentiation and reproductive potential of ex vivo expansion than bone marrow stem cells and peripheral blood stem calls. The preservation of cord blood stem cells and umbilical cord blood transplantation, and other clinical applications have made significant progress, but blood is also facing many problems. This article reviewed a variety of cord blood stem/progenitor calls of the biological characteristics of liver calls proliferation, differentiation, and the building of umbilical cord blood bank of neurology in clinical application.

Result Analysis
Print
Save
E-mail